Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant COVID-19 vaccine (chimpanzee adenovirus vector) for inhalation
- Development stage
- Phase 1
- Lead developer
- Wuhan BravoVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
RCVi is a recombinant COVID-19 vaccine utilizing a non-replicating chimpanzee adenovirus vector to deliver the genetic sequence of the SARS-CoV-2 spike protein. Developed by Wuhan BravoVax, this vaccine is specifically formulated for administration via inhalation to induce mucosal immunity in the respiratory tract, in addition to systemic immune responses. The use of a chimpanzee adenovirus vector is intended to circumvent pre-existing immunity to human adenoviruses, which can limit the effectiveness of human adenovirus-based vaccines. As of 2023, the vaccine is being evaluated in Phase I clinical trials as a booster for individuals who have previously received primary vaccination with authorized COVID-19 vaccines.
- Other names
- Recombinant COVID-19 Vaccine (Adenovirus Vector) for Inhalation
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on recombinant COVID-19 vaccine (chimpanzee adenovirus vector) for inhalation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant COVID-19 vaccine (chimpanzee adenovirus vector) for inhalation.